Company news

Emergent BioSolutions Inc. news in 2026

Emergent BioSolutions Inc.'s news releases, calls and decks from 2026, newest first.

View company

Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War

November 4, 2026

Emergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. Lindahl

October 16, 2026

Emergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026

October 15, 2026

Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility

September 15, 2026

Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes

September 3, 2026

Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)

September 1, 2026

Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray

August 31, 2026

Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day

August 31, 2026

Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment

August 5, 2026

Emergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026

July 22, 2026

Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government

June 29, 2026

Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy

May 28, 2026

Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]

May 18, 2026

Emergent BioSolutions Reports First Quarter 2026 Financial Results

April 30, 2026

Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox

April 30, 2026

Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142

April 29, 2026

Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States

April 28, 2026

Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026

April 16, 2026

Emergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Program

April 9, 2026

Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness

April 7, 2026

Emergent BioSolutions Participates in Upcoming International Preparedness Conferences

April 2, 2026

Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures

March 25, 2026

Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors

March 3, 2026

Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results

February 26, 2026

Emergent BioSolutions Announces New $50 Million Stock Repurchase Program

February 26, 2026

Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada’s Leadership in Health Preparedness

February 26, 2026

Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks

February 12, 2026

Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

February 12, 2026

Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN® Nasal Spray to be Packaged in a New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday Preparedness

January 14, 2026

Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation

January 12, 2026

Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026

January 8, 2026

Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa

January 8, 2026

Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

January 7, 2026

Calls in 2026

Decks in 2026